Cyagen    



Contact us for a free consultation on your CAM/CGT projects.

Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative cell and gene therapy (CGT) solutions for research and development (R&D), including: disease model development, AAV discovery, drug efficacy studies, and more. The company has established extensive cooperations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles, many of which were in the three major journals of CNS (Cell, Nature, Science). From its robust foundation in animal model development, to implementation of artificial intelligence (AI)-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.

One-Stop Solutions for All Research Model Needs

Our comprehensive services cover the entire process of model generation: from transgenic/gene targeting strategy design, through model development, breeding, cryopreservation, and phenotype analysis. Our CRO service platforms provide everything required for drug discovery and preclinical research, including specialty cell and gene therapy (CGT) therapeutic areas, such as ophthalmology, immuno-oncology, and neuroscience.

Brands: Rare Disease Data Center (RDDC): https://rddc.tsinghua-gd.org/ Free to use AI-guided genetic analysis tools for rare disease researchers.


 Videos

Accelerate Your Research Goals with Cutting-edge CRO Services from Cyagen

 Show Specials

  • Custom Animal Models: KO, KI, cKO, cKI, Point Mutation, and Humanization - save up to 15% | CyagenFor the Mix-and-Maximize Savings Event, our Model Design Specialist (MDS) team will work with you to identify your project needs and generate a quote that provides you with the maximum savings across a range of model generation services. Contact us to see how you can save up to 15% on your CAM project and even receive an additional $2k credit for add-on services – over $6,700 in savings available for TurboKnockout® projects.

    Custom Animal Model Savings – Maximum Discounts Available*:

     Save up to 15% on your CAM projects: TurboKnockout®, ESC gene targeting, CRISPR, transgenic, PiggyBac transgenic, etc. Check "Custom Animal Model Capabilities" to learn more details.
     Up to $2k credit towards add-on services: downstream (homozygous) breeding, cryopreservation, and more

    *Maximum discounts vary depending on CAM project type(s). For example, transgenic services may only receive a maximum of 5% off.

     Promotion Period: Offer ends June 30, 2023; quote must be requested before the deadline.
     Eligibility: Attendees of ASGCT; Academic customers in US & EU – use promotional code "ASGCT23" when placing inquiry. Contact us for eligibility in other regions or for commercial use.

    Our MDS representatives are standing by to provide you with a complimentary animal model project consultation and custom quote – including discounts tailored to provide the greatest savings for your research plan. Request a quote before June 30, 2023 to qualify for the Mix-and-Maximize Savings Event.

    Contact us for a free technical consultation and quote.

  • The Cyagen Knockout Catalog Models repository provides ready-to-use gene knockout (KO) mice with rapid turnaround and competitive prices.

    To serve researchers interested in our high-quality genetically modified mouse models, we are opening an exclusive “Knockout Catalog Models Super Savings Event” offer for a $2,000 credit voucher on eligible gene knockout (KO) mice. Submit the form using the code "ASGCT23" to get a $2,000 credit voucher for gene knockout (KO) mice from the Cyagen Knockout Model Repository.

    • ■ Promotion Period: Offer ends June 30, 2023
    • ■ Eligibility: Academic customers in US & EU. Must submit form with code "ASGCT23" before June 30, 2023, in order to receive a voucher. Contact us for eligibility in other regions or for commercial use.

    Voucher Terms and Conditions:
    • Period of Validity: This voucher is valid on projects initialized by 9/30/2023. 
    • This voucher is non-refundable, non-transferable and is valid for a single transaction only. It has no cash value.
    • This voucher is not valid in conjunction with other special promotions or discounts.

    In addition to our Catalog Knockout Models, we provide a variety of Animal Model Supporting Services, such as homozygous breeding.

    Whether you are seeking funding or planning for your next research project, Cyagen is here to help. For consultation and order, please email animal-bank@cyagen.com.

     

  • Mouse

    Are you considering custom animal models for your next research project? Do you want to maximize your research budget? Interested in securing the added confidence of a guaranteed genotype*?

    Lock-in the best deal with our limited-time “Price Match + 10% Off” custom animal model (CAM) project promotion! Get the most cost-effective answer to all of your CAM project requirements by allowing us to match any quote from commercial providers (for equivalent services) with an additional 10% off.

    As a one-stop shop for research model solutions, Cyagen offers complete outsourcing for all your animal model needs through The Alliance—a unique partnership that provides specially tailored model generation and colony management solutions for the academic and non-profit markets. Extend your research budget with cost-effective and reliable CAM development projects and supporting services.

     Promotion Period: Offer ends June 30, 2023.

     Eligibility: ASGCT attendees: use code "ASGCT23" when submitting inquiry. Academic end clients in Europe, North America, and South America.

    Our custom animal model services offer the following advantages:
      Price Matching + 10% Off (equivalent scope of work)
    Our team will price match CAM project quotes from commercial providers and give you an extra 10% discount to help ensure researchers get the best deal for their study. Bring your quote, and we will match it.
      Guaranteed Project Genotype

    Cyagen’s gene editing services are unparalleled in delivering research-ready rodent models with a guaranteed genotype. To optimize the process of generating your new model, Cyagen provides a unique genotype guarantee* - confirmed using standard PCR validation of the expected fragment size to match the original project strategy - to give you further peace of mind.

    *Does not guarantee biological outcome (i.e., transgene expression levels) and is limited by modifications that may negatively affect the health and viability.

      Fast Project Scoping & Quotes
    We will work with you to identify the optimal CAM project strategy to serve your research goals and suit your budget.
      Comprehensive Capabilities
    Provides researchers with access to a comprehensive toolkit of technologies, including but not limited to: CRISPR/Cas9, transgenic technology, PiggyBac, and embryonic stem cell (ESC)-based homologous recombination (HR).
  • The purpose of cellular gene editing is to modify the characteristics and functions of cells by targeted alteration of their genome. Cyagen offers a range of custom gene editing services, including gene knockouts (KO), knock-ins (KI), point mutations (PM), overexpression (OE), and shRNA interference, to deliver general cell lines and induced pluripotent stem cells (iPSCs) used for preclinical studies. These services are widely used in life science research and biotechnology development, such as gene function studies, drug screening, and gene therapy. Order Cyagen’s gene editing services by May 24 to receive a special discount!

  • Use the code "ASGCT23" for an exclusive 30% off our standard prices for genetic engineering and viral packaging services!

    Offer valid only for first-time orders from ASGCT 2023 attendees. Submit the code "ASGCT23" with your project request before the offer ends. Discount code valid until June 30, 2023.

    Custom Mouse Models: https://www.cyagen.com/us/en/services/mouse-models.html

    Custom Rat Models: https://www.cyagen.com/us/en/services/rat-models.html

    Custom Cell Lines: https://www.cyagen.com/us/en/services/animal-models-downstream-services/solution-for-cell-therapy/cell-lines.html

    CRO Services for Immune Cell Therapy: https://www.cyagen.com/us/en/services/cell-therapy-solutions.html

    Virus Services: https://www.cyagen.com/us/en/services/virus-services.html

    Adeno-associated virus (AAV) Packaging: https://www.cyagen.com/us/en/services/virus-services/adeno-associated.html

    Lentivirus (LV) Packaging: https://www.cyagen.com/us/en/services/virus-services/lentivirus-packaging.html

    Adenovirus (AdV) Packaging: https://www.cyagen.com/us/en/services/virus-services/adenovirus-packaging.html


 Press Releases

  • Our comprehensive services cover the entire process of model generation: from transgenic/gene targeting strategy design, through model development, breeding, cryopreservation, and phenotype analysis. Our CRO service platforms provide everything required for drug discovery and preclinical research, including specialty cell and gene therapy (CGT) therapeutic areas, such as ophthalmology, immuno-oncology, and neuroscience.


     

    Innovative "AI+CGT"service platform

    Combining wet-lab experiments, bioinformatics and AI, our team has collected a large amount of data and built many proprietary AI models for cell and gene (CGT) therapy research, providing a range of preclinical services including: prediction of human gene mutation pathogenicity, design of mouse disease models, and accelerate the discovery of novel CGT drugs, such as adeno-associated virus (AAV) vectors and CAR-T cell therapies.

    For example, utilizing AI and single-cell RNA-sequencing technologies, Cyagen's high-throughput AAV vector discovery platform helps overcome the present limitations of gene therapy R&D by quickly identifying next-generation AAV capsids that have enhanced tissue targeting capability, tissue specificity, and productivity. Cyagen has produced substantial experimental data for AI model training and developed proprietary machine learning algorithms to accelerate the AAV capsid identification and optimization processes compared to traditional directed evolution methods.

    Preclinical Ophthalmology Research Solutions

    There are a large number of patients with hereditary ophthalmic diseases worldwide. Due to the limited effectiveness of traditional treatments, the world has turned to gene therapy drugs. As of 2021, Ophthalmology ranks second in the gene therapy pipeline according to number of treatments in development. There are many gene therapy drugs currently on the market, but basic research and clinical translation in ophthalmology faces many difficulties, such as complicated operation, long production period of experimental models, and expensive equipment.


    As a comprehensive contract research organization (CRO) solution provider, Cyagen recognizes ophthalmic diseases as a breakthrough point for gene therapy and has established an ophthalmic gene therapy platform to overcome the above obstacles. We have equipped the platform with state-of-the-art ophthalmic instruments for small animals and an experienced professional team. With 16 years of gene editing model construction experience, Cyagen can provide you with an array of standardized preclinical research solutions for ophthalmic gene therapy.

    Learn more>>

    Download our Opthalmology Brochure>>

    Have questions or need help with your ophthalmology development program?

    Ask Our Experts >>

    Immune Cell Therapy CRO Services

    At the same time, Cyagen also provides full support for cell therapy R&D. Cyagen’s fully-humanized antibody screening platform allows discoveries of novel antibody drugs and CAR-T cell therapy drugs. Combined with our virus packaging, mouse model construction and pharmacodynamic CRO capabilities, we provide one-stop solutions for all stages of preclinical cell therapy R&D.

    Learn more>>

    Cyagen Knockout Catalog Models: Extensive KO/cKO Mouse Strain Library Resource

    The Cyagen Knockout Catalog Models repository provides a searchable listing of over 16k mouse strains in more than 20 research fields, including oncology, cardiology, and neurology. You can quickly query the required genetically engineered global knockout (KO) mouse, conditional knockout (cKO/floxed) mouse and microRNA KO mouse strains by simply entering the gene name. The powerful database offers you a more convenient experience by streamlining the process of identifying KO mouse models and ordering them for research.

    Cyagen subdivides different mouse models into applied research fields and provides detailed information about the backgrounds and associated applications of the models to help simplify the model selection process.

    Expertly customized mouse models

    Cyagen has 16 years of experience in the field of model animal customization and has developed a number of technological innovations. Cyagen can develop any desired mouse models for customers through CRISPR gene editing, TurboKnockout gene editing, transgenic and other technologies. Cyagen’s innovative genetic modification techniques allow easier, faster and more efficient knock-in (KI), KO and other gene editing capabilities during mouse model generation without the concerns of off-target effects or patent disputes.

    One-stop in vivo and in vitro drug efficacy evaluation platform

    Cyagen has established a one-stop CRO platform for drug development, screening, and drug efficacy evaluation covering a wide range of research areas, including oncology, immunology, metabolism, cardiology, neurology, ophthalmology, and infectious diseases. Cyagen’s one-stop in vivo and in vitro drug efficacy service platform can provide services including immunological testing, physiological and biochemical testing, behavioral testing, cell function testing, molecular biology testing, in vivo imaging, pathology and other specific disease phenotype analyses.

    Animal disease models are an indispensable tool to study the mechanisms of human disease development, and can be used for drug screening and efficacy evaluations. Choosing the right disease animal models can accelerate the development of new drugs. To provide the highest-quality models to researchers, we continuously optimize our gene editing technologies and recruit seasoned specialists to support our scientific innovation together.

    Rare Disease Data Center (RDDC): AI-enabled bioinformatics research tools

    Publicly launched in February 2022, the Rare Disease Data Center (RDDC) has been developed by the artificial intelligence innovation center of Tsinghua Pearl River Delta Research Institute and Cyagen as part of their participation in the Rare Disease Gene Therapy Alliance, providing support for improved dissemination of biological and genetics information and knowledge. The RDDC focuses on providing comprehensive genetic data visualization & AI-powered pathogenic analysis tools for rare disease research. It integrates all reported rare disease data and gene information, including: epidemiological data, disease-related gene profile, variants, phenotypes, drug developmental outlines, and disease-associated mouse models. The purpose of RDDC is to help doctors, researchers, pharmaceutical companies, as well as patients and their families, to quickly analyze and understand any rare disease. It also integrates China’s domestic rare disease-related data resources to provide a comprehensive data profile for scientific and clinical research of rare diseases.

    Our Capabilities:

  • Recently, Cyagen and Guangdong Landau Biotechnology Co., Ltd. (hereinafter referred to as "Landau Biotech") strengthened their strategic partnership on the basis of the original strategic cooperation. A new consensus will be reached on the joint focus for the development of AAV gene therapy vectors, and will fully utilize the collective resources, technologies, and brand advantages of both parties.

    This cooperation aims to combine the advantages of Cyagen's gene therapy AI high-throughput AAV capsid evolution technology platform and the completely closed loop of non-human primate model platform of Landau Biotech to jointly develop highly efficient AAV capsids to support the development of gene therapy products. The cooperation between the two parties can give full play to the advantages of both parties and promote the development of fast and efficient AI-AAV capsids.

    Promote cooperative development to help break through the gene therapy industry bottleneck

    Cyagen considers ophthalmic diseases and neurological diseases as a breakthrough point for gene therapyRelying on internationally renowned refined small animal ophthalmic equipment, senior professional talent resources and rich experience in gene editing model construction, it has established a gene therapy CRO service platform, from the design and optimization of AI-assisted AAV capsid protein to virus packaging and production, and the evaluation of gene therapy effectiveness, which fully supports the discovery, development and application of gene therapy drugs. Additionally, with the help of its own mouse resource library, model customization platform and standardized service phenotype analysis laboratory, a CRO service platform for neurological diseases featuring neurodegenerative diseases has been established to help researchers more deeply decode neuroscience research.

    Landau Biotech concentrates resources to advance non-human primate research, accelerate the creation of disease model animals, and lead major breakthroughs original innovation achievements for China; Introduces, collects, and organizes animal model resources at home and abroad, and establishes a national animal model resource bank; Building a complete industrial chain from basic research, pilot production, through clinical trials, which promotes the cross-integration of industries with new technologies such as big data, cloud, and AI to provide high-quality, cost-effective animal resources and experimental service systems for universities and scientific research institutions.

    Based on Cyagen's AI high-throughput AAV capsid evolution technology platform, ophthalmology and neuroscience research platform, as well as Landau Biotech's non-human primate model breeding and research platform, the two parties have a good foundation established with their in-depth cooperation in the research and development of AAV gene therapy vectors. On this basis, the two parties will fully integrate and optimize resources to provide better delivery vehicles for the development of the gene therapy industry in important disease fields such as ophthalmology, neurologyhepatology, and myology, and explore breakthroughs to solve the gene therapy industry bottleneck of hematological applications as soon as possible.

    Working together to seek innovation in gene therapy drugs

    Mr. Lance Han, chairman of Cyagen, said, "In recent years, the gene therapy industry has continuously ushered in breakthroughs, and many people are paying attention to it. It is hoped that through the cooperation of research centers, preclinical CROs, and pharmaceutical companies, this innovative drug field will move faster towards industrialization. For us, Landau Biotech is an ideal partner. Relying on the leading edge of primate experimental animals, the disease research and pharmacological efficacy detection models assisted and participated in by Landau Biotech have performed well in helping the research and development of genetic drugs. It is a great pleasure to be able to successfully reach cooperation with Landau Biotech to collaborate and innovate on the AAV capsid development project, so as to achieve the common goal of going all out for gene therapy research and development. "

    Mr. Lei Fan, chairman of Landau Biotech, noted, "Everyone knows that the effectiveness and safety of technology platforms are crucial to the research and development of gene therapy; In the current clinical research of gene therapy, AAV delivery vectors are the most widely used and most important. From the perspective of technology platform, Cyagen has been insistent on independent innovation and technical research for the key technology of AI high-throughput AAV capsid evolution. Therefore, we are quite optimistic about this collaboration with Cyagen on the development of AAV gene therapy vectors. "

    About Cyagen

    Founded in 2006, Cyagen is an innovative CRO company that provides genetically modified rodent models and innovative one-stop cell and gene therapy solutions for R&D, including: disease model development, AAV discovery, drug efficacy studies, and more. Combining  animal model expertise with in-depth exploration of artificial intelligence, Cyagen is at the forefront of the industry in the field of gene editing animal models, developing comprehensive AI tools and services that accelerate the development of new drugs with data, algorithms, and research models. Cyagen’s capabilities meet the needs of customers in the field of basic research and new drug research and development of animal models, examples include:  animal model resource library, model customization, breeding, sterile mouse technical services to phenotypic function verification, and more. At the same time, Cyagen has continuously enriched its product lines, strengthened its advantages in data and models, and proactively deployed the gene therapy and cell therapy platformswhich integrate with target prediction and verification, virus vector development, evaluation model construction, and effectiveness evaluationin anticipation of the rapid evolution of gene and cell therapies.

    Cyagen currently has over 900 employees and multiple facilities with a total scale of over 40,000 square meters. The company has established extensive cooperations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles - including the three major journals of CNS (Cell, Nature, Science). From its foundation in animal model development, to implementation of AI-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.

    About Landau Biotech

    The development history of Landau Biotech can be traced back to 1980. It is one of the earliest professional institutions engaged in the breeding and research of primate experimental animals in China, and it is also a leading research and development center for experimental monkey disease models in China. Landau Biotech is committed to providing services such as pharmacology and pharmacodynamics research, drug metabolism research, early drug screening, behavior, imaging, ophthalmology experiments and surgical operations for scientific research institutions, biomedical companies and other customers. Since 2019, Landau Biotech has cooperated with a number of scientific research institutions and scientist teams to carry out in-depth construction of common technology platforms.

    During the 2020 epidemic, Landau Biotech has cooperated with the Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences, the Institute of Human Virology of Sun Yat-sen University and other units to carry out novel coronavirus vaccine research. The research results were published in the top international journals "Nature" and "Immunity" respectively, and recognized as "Guangdong Primate Experimental Animal Disease Model Engineering Technology Research Center" by the Guangdong Provincial Department of Science and Technology. It also presides over and participates in a number of scientific and technological plan projects including the National Twelfth Five-Year "New Drug Creation" major special project and the National Ministry of Science and Technology Support Plan. Ten items have achieved great results in the construction of research and development institutions.

    Landau Biotech has more than 40 years of scientific research experience and complete international qualification certifications. With the most complete license resources in the industry, it has "Wild Animal Domestication And Breeding License", "Experimental Animal Production License", "Experimental Animal Use License", "High-Tech Enterprise Certification", etc. In 2011, the company became the first group in South China to obtain AAALAC certification. In November 2022, Landau Biotech’s Phoenix Laboratory became the first laboratory in Guangdong to successfully pass CNAS-CL06 on-site accreditation.

  • Original Article


     

    Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders.

    Under the terms of the agreement, Cyagen will apply its proprietary artificial intelligence (AI)-powered high-throughput platform to discover novel AAV vectors with optimized tissue targeting capability, tissue specificity, and productivity. Cyagen and Neurophth will both be responsible for evaluating the functional properties of the novel AAV vectors in rodent and NHP models, and Neurophth will be responsible for conducting clinical trials and commercialization for gene therapy products developed using Cyagen’s novel AAV capsids. Cyagen could receive research phase and clinical phase milestone payments, as well as sales royalties that may exceed $140 million.

    Solving the Challenges of Gene Therapy Research and Development

    Utilizing AI and single-cell RNA-sequencing technologies, Cyagen’s high-throughput AAV vector discovery platform helps overcome the present limitations of gene therapy R&D by quickly identifying next-generation AAV capsids that have enhanced tissue targeting capability, tissue specificity, and productivity. Cyagen has produced substantial experimental data for AI model training and developed proprietary machine learning algorithms to accelerate the AAV capsid identification and optimization processes compared to traditional directed evolution methods.

    Recognizing the growing potential for ophthalmic gene therapy, Cyagen’s Ophthalmology Research Solution platform is fully equipped with state-of-the-art ophthalmic instruments and an experienced professional team.

    "Gene therapy has demonstrated great promise and potential for treating genetic ophthalmic diseases, and the ophthalmic gene therapy market has expanded exponentially in the past few years,” Lance Han, president of Cyagen, said. “Together with Neurophth, we will develop the world’s best AAV ophthalmic gene therapy products and bring brightness back to patients all over the world."

    “Neurophth hopes to seek like-minded partners to work together to achieve breakthroughs in ophthalmic gene therapy development, and I think Cyagen is our ideal companion on the road ahead,” said Bin Li, Founder, Chairman and CEO of Neurophth.

    About Cyagen

    Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative one-stop cell and gene therapy solutions for R&D, including: disease model development, AAV discovery, drug efficacy studies, and more. Cyagen currently has over 900 employees and multiple facilities with a total scale of over 40,000 square meters. The company has established extensive cooperations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles - including the three major journals of CNS (Cell, Nature, Science). From its foundation in animal model development, to implementation of AI-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.

    About Neurophth

    Neurophth is China's leading gene therapy company focusing on ophthalmic diseases. NR082 (NFS-01), Neurophth' core product, designed to treat ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON), has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and is the first Chinese gene therapy new drug that has been granted IND approval for clinical trials by Chinese National Medical Products Administration (NMPA) and the US FDA. At present, the first patient has been dosed in the Phase III clinical trial in September 2022. The company's pipeline also includes ND1-mediated LHON (the company's second new drug with ODD granted by the US FDA), autosomal dominant optic atrophy, optic nerve protection, vascular retinopathy and other preclinical candidates.
     

    Preclinical Ophthalmology Research Solutions

    As a comprehensive contract research organization (CRO) solution provider, Cyagen recognizes ophthalmic diseases as a breakthrough point for gene therapy and has established an ophthalmic gene therapy platform to overcome the above obstacles. We have equipped the platform with state-of-the-art ophthalmic instruments for small animals and an experienced professional team. With 16 years of gene editing model construction experience, Cyagen can provide you with an array of standardized preclinical research solutions for ophthalmic gene therapy.

    Gene Therapy Research Solutions

    As a comprehensive solution provider, Cyagen has established an innovative CRO platform that provides researchers with leading-edge genetically modified model services. We have accumulated a large amount of data on biological information and gene editing over the past decade in our continuous dedication to cell and animal models which have allowed us to play a leading role in the gene-editing field.

    Cyagen provides one-stop solutions for gene therapy development to meet the needs for all levels of research. Our services include CRISPR Cas9 Screening & Target Validation, Custom Mouse Model Generation, Efficient Adenovirus/Lentivirus Packaging of adeno-associated virus (AAV), lentivirus (LV), adenovirus (ADV), Pharmacology and Pharmacodynamics (PD) Studies, and more. We hope that our services can improve the efficiency of gene therapy research results.

    Adeno-associated Virus Packaging

    Adeno-associated viruses (AAVs) are promising therapeutic viral vectors. Cyagen can provide adeno-associated virus vectors design and delivery services. For AAV virus packaging, we adopt a three-plasmid co-transfection method. The advanced purification process can provide customized AAV packaging services with high purity, high titer, and different serotypes. It is especially suitable for in vivo animal experiments and can meet the personalized choices of gene therapy researchers.

    >> Check out more details on Adeno-associated virus packaging

  • Have you ever wondered what the future of science education looks like? Many envision a future of readily accessible science knowledge and facts presented by intelligent, interactive teachers. Given the limited time and resources available from top teaching talent, there is an increasing demand for engaging scientific learning that could be supported by the growing power of machine learning and artificial intelligence (AI) platforms.

    To this end, Cyagen and Cyrinn have combined their expertise to create “AI Marvin,” the world's first AI Chief Scientific Officer to focus on the dissemination of biological science knowledge focusing on genetics research topics. Meet AI Marvin and the man behind the scientific magic, Dr. Ouyang!

    Introducing AI Marvin

    Our real-life Chief Scientific Officer, Dr. Yingbin (Marvin) Ouyang, not only contributes his likeness, but also imparts his knowledge through AI Marvin’s presentations. Dr. Marvin Ouyang has been dedicated to the development of genetically engineered rodent models for the past 20 years, developing hundreds of transgenic and KO/KI mouse/rat models for biomedical research and drug development. Dr. Ouyang has published many papers in high-impact academic journals such as PNAS and JBC; his technical services have been directly cited hundreds of times by top international journals, including Nature.  He has now dedicated significant time to help teach the AI that will serve to educate the masses and provides ongoing support with production of educational topics.

    Subscribe to Cyagen’s YouTube to get notifications for all our new videos, covering scientific topics related to genetic engineering, featured genes, disease pathologies, cell and gene therapy (CGT) research, and CAR-T cell therapy development.
     

    AI Marvin is the world's first AI Chief Scientific Officer, created by Cyagen and Cyrinn, to focus on the dissemination of biological science knowledge, with a focus on research involving genetically engineered disease models for effective therapeutic evaluations. Through humorous and simple teaching methods, it provides a human connection that stimulates the audience's curiosity and desire for knowledge. This might help people establish a scientific attitude and thinking, facilitating a strong understanding of the scientific process and innovative academic thinking through access to high-quality popular science education. In the future, AI Marvin will also have its own 3D image, which will further enrich the range of content expression and better serve popular science education by appealing to even wider audiences.
     

    QUESTIONS? Ask AI Marvin by tweeting us @CyagenBio with the hashtag #ASKAIMARVIN!
     

    AI Marvin Playlist (YouTube) 
     

    At present, cell therapy is mostly used in the field of oncology, in which it is necessary to construct stable tumor cell models and animal models to evaluate the therapeutic effect. Chimeric antigen receptor (CAR) T cell therapy has made great strides in hematological malignancies, with approved therapies in certain leukemias, lymphomas, and more recently myeloma, with very high overall response rates.

    In vitro cell models provide a variety of detection methods for evaluating the effectiveness and specificity of CAR-T therapy. For in vivo evaluation models, it is required that the model have a corresponding immune environment to avoid causing CAR T-cell rejection, and the experimental animals must have a stable living condition. In addition, a mouse model of homologous tumor transplantation can also be used to verify the mechanism and treatment principles of CAR-T.

    Quick Q&A Series: CAR T Cell Therapy

    As one of the fastest growing areas of pharmaceutical research and development, CAR T cell therapies are demonstrating great promise for treating more than just blood cancers. There are many factors that affect the effectiveness of CAR-T cells, such as transfection efficiency, culture conditions, and cell types. In this series, AI Marvin answers many common questions about CAR T cell therapy research.

    Subscribe to Cyagen’s YouTube to get notifications for all our new videos, covering scientific topics related to genetic engineering, featured genes, disease pathologies, cell and gene therapy (CGT) research, and CAR-T cell therapy development.
     

    QUESTIONS? Ask AI Marvin by tweeting us @CyagenBio with the hashtag #ASKAIMARVIN!
     

    1. How to Choose CAR-T Target Cells

    In some cases, after selecting the indications and targets there are a lack of suitable natural tumor cells as target cells. In this situation, how do researchers select the target cells?

    In this case, we can choose to construct a corresponding stable cell line. The selection of the cell line type should be as consistent as possible with the indication and the study. For example, if the indication for the study is liver cancer, a corresponding liver cancer cell line can be selected as the stable cell lines for this study. In this way, the cell line can also be used for downstream in vivo and anti-tumor activity evaluation experiments. In addition, if we only make some simple anti-tumor activity evaluation and specificity verification work we can also choose more commonly used tumor cell lines such as 293T and CHO-K1 these cell lines are easy to be infected by lentiviruses so it is easy to obtain stable cells which can save time and costs.
     

    2. How to Verify the Specificity of CAR T Cells

    Bispecific CAR-T cell therapy may often be selected due to the improved cytolytic activity that may be achieved. However, researchers may face a lack of cell lines that co-express dual targets. How do researchers choose the target cell and verify the specificity of the CAR-T cells constructed?

    Due to the heterogeneity of target antigen expression in tumor cells  and the problem of antigen escape during CAR-T cell therapy, there are more and more studies on bispecific CAR-T to solve this problem. In the absence of suitable target cells for dual-target CAR-T cell research, we can solve this problem by constructing a stable cell line. The cells used to construct a stable cell line may be derived from the adaptation of disease tumor cells. To study the function of bispecific CAR-T cells, we can also construct a cell line with single and dual expressing antigen, So the specificity of bispecific CAR-T cells can be assessed to some extent after lysis of these cell lines in vitro.
     

    3. CAR-T Cells Antigen Loss and Validation of Anti-Tumor Effects

    How can we fix the loss of stable cell lines’ surface antigens?

    If the stable cell lines have eukaryotic resistance it can be maintained by adding corresponding antibiotics. However the dose of antibiotics needs to be optimized in order to achieve a better maintenance effect, but if not, several times enrichment can be performed by flow sorting, which may solve the problem of antigen loss in stable cells. In addition the cell lines with stable antigen expression can be obtained by screening the clones.

    How can we choose the appropriate target cells to prove the specificity of the anti-tumor effect of car T cells?

    Well we can both select cell lines that express or not express the target antigen and then use CAR-T cells to kill these two types of cells respectively and according to the killing results determine whether the anti-tumor effects of CAR-T cells is specific or not.

    Cell & Animal Models for CAR-T Cell Therapy and Immuno-oncology

    As a global research services company, Cyagen provides one-stop research service solutions supporting CAR T and other cell therapy development programs, including: CAR virus preparation, the construction of tumor immune cells and animal models, and the entire process of in vivo/in vitro drug efficacy evaluation. Our services accelerate the development of your CAR T and cell therapy research.

    Cyagen has been committed to the establishment of gene-edited cells and animal models. We have an experienced team of experts and a mature technology platform that provides cell models and animal models for the regulation of target gene expression. For CAR-T and cell therapy research, we have established catalogs with thousands of cell and mouse models for tumor immune research, and provide preclinical in vivo/in vitro pharmacology evaluation services for domestic and foreign pharmaceutical companies, biological companies, scientific research institutes, and hospitals. For example, C-NKG mice are a severe combined immunodeficiency (SCID) model developed by Cyagen, which are without murine T/B/NK cells and have defective myeloid components. C-NKG mice can be used to construct various CDX models and reconstruction of the human immune system in a mouse model.

    In vivo Evaluation Models
     

    Animal Model Services:

    • Immunodeficient Models: BALB/c nude mice, NOD scid mice, C-NKG mice
    • Humanized immune system (HIS) models: Hu-PBMC mice, Hu-HSC mice
    • Cell Line-derived Tumor Xenograft (CDX) models: Subcutaneous solid tumor model, In situ solid tumor model, Hematoma model
    • Homologous tumor mouse models: Lung cancer, colorectal cancer, breast cancer, melanoma, and other homologous tumor models


    Advantages:

     

    Cell Line-derived Tumor Xenograft (CDX) models
    • The mechanics of tumor formation among a variety of tumor cells can simulate solid tumors and hematomas.
    • It can effectively support the growth of various tumor cells and CAR-T cells.
    • The CDX model is stable, the experiment is highly reproducible, and the result data is reliable.
    • Highest standards across animal experiment operations and breeding environment.
    Humanized Immune System (HIS) Models
    • The survival rate of mice is high, and the experimental window is long.
    • Different reconstruction methods of PBMC and HSC can be provided with a high degree of humanization.
    • The model has high uniformity and the data is more convincing for translational research.


    In vitro Evaluation Models

     

    Cell Model Services:

    • Tumor cells expressing CAR-T targets
    • Luciferase labeled tumor cells
    • CAR-T cell construction
    • Overexpression stable transgenic cell Line services
       

    Advantages:

    • Antigen expression is stable: The degree of antigen expression is high, and it still maintains stability after multiple passages.
    • High expression efficiency of CAR molecules: All T cell subtypes have significantly high expression of CAR molecules.
    • One-Stop Services: Multiple verification schemes, complete model construction and identification system.

       

    For more information, contact our experts to inquire about our services or obtain a quote for your project.

    Follow us on Social Media:

    YouTube: https://www.youtube.com/c/Cyagen

    Twitter: https://twitter.com/cyagenbio

    Linkedin: https://www.linkedin.com/company/cyagen-biosciences

    Facebook: https://www.facebook.com/CyagenBiosciences

    Subscribe to our emails: https://www.cyagen.com/us/en/community/edm-subscribe.html

    Original Article

  • Recently, researchers announced that they have found a new target for inhibiting vascular endothelial growth factor (VEGF), which can improve the symptoms of ophthalmic diseases. This is achieved by affecting the release of VEGF and choroidal neovascularization through fat mass and obesity-associated protein (FTO) inhibition. These findings provide a new research mechanism for ophthalmic treatment. The relevant research results were published in the February 2023 issue of "Signal Transduction and Targeted Therapy", a sub-journal of "Nature".

    VEGF is a group of important regulatory factors that can stimulate the growth of new blood vessels (angiogenesis) and increase the permeability of existing blood vessels. It plays a critical role in normal development and wound healing. VEGF includes several types, such as VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and PLGF. In drug research, VEGFA is the most common type, and it is involved in endothelial cell proliferation, migration, and microvascular formation. When VEGFA is overexpressed in the eye, it can cause abnormal blood vessel proliferation, vascular leakage, and other ophthalmic diseases, such as macular degeneration, diabetic retinopathy, corneal neovascularization, and so on.

    1. Research Progress of VEGF-targeted Drugs

    So far, multiple VEGF drugs have been approved for the treatment of macular degeneration, tumors, and other vascular-related diseases. From the research and development perspective, the main focus is on two areas: ophthalmic diseases and tumors.

    The application of VEGF drugs in ophthalmology is mainly targeted at some macular-related diseases, such as wet age-related macular degeneration and diabetic retinopathy. The common feature of these diseases is the neovascularization and leakage of capillaries in the macular region, leading to retinal edema and vision loss. VEGF is one of the important factors causing abnormal blood vessel generation. Therefore, the use of VEGF drugs can inhibit abnormal blood vessel generation, reduce leakage, and improve patients' vision and ophthalmic symptoms.

    Common VEGF targeted drugs used for ophthalmic diseases include aflibercept, conbercept, bevacizumab, and ranibizumab. In addition, many VEGF drugs are currently undergoing clinical trials. According to data from ClinicalTrials, there are more than 600 clinical trials related to these drugs.

    2. Phenotypically Stable Humanized VEGFA Mice

    To better investigate the pathological mechanisms of ophthalmic diseases and help develop targeted drugs, Cyagen has established a model of human VEGFA gene CDS sequence expression driven by a rod cell-specific promoter in C57BL/6J mice, to obtain transgenic mice that overexpress the human VEGFA gene specifically in the retina. This humanized VEGFA (hVEGFA) overexpression mouse model can develop spontaneous vascular lesions on the intact eye structure, which can be used for drug evaluation and related mechanism research of neovascular-related ophthalmic diseases. In addition, using their self-developed hVEGFA mice, Cyagen has conducted positive drug tests, such as aflibercept and bevacizumab, to evaluate the inhibitory effects of targeting hVEGFA.

              Figure 1. The construction method of hVEGFA mice.
     

    Cyagen's ophthalmic CRO platform has a team of ophthalmic experts trained to perform experimental operation with our sophisticated instruments and equipment. We can perform in vivo ophthalmic detection techniques for hVEGFA mouse models, including eye surface observation, intraocular pressure measurement, fundus photography, image-guided optical coherence tomography (OCT), full-field electroretinogram (ERG), and fundus fluorescein angiography (FFA), optokinetic response (OKR), and more. At the same time, they have professional pathology and molecular detection techniques, including evaluation of retinal hVEGFA expression levels, FITC-Dextran perfusion retinal flat mount, and hVEGFA expression levels in eye tissue sections to evaluate vascular lesions.

    3. Humanized VEGFA Mouse Model Verification Case Study

    According to the experimental verification by the Cyagen technical team, the F0 generation of hVEGFA mice showed significant, clear, and stable fluorescent leakage spots in the fundus, similar to the phenotype of neovascular age-related macular degeneration. The F1 and F2 generations of mice can stably inherit the parental phenotype, making them suitable for preclinical studies such as VEGFA drug efficacy evaluation.

    FFA (Fundus fluorescein angiography) results showed that there were vascular lesions in the mouse fundus and widespread leakage of fluorescein sodium.

                                                      Figure 2. Fundus fluorescein angiography results of hVEGFA mice (F0).


    OCT showed mild disruption in the choroidal region.

    Figure 3. OCT results of hVEGFA mice (F0).
     

    ERG showed no significant difference in retinal potentials compared to WT mice.

    Figure 4. ERG results of hVEGFA mice (F0).

     

    FFA (Fundus fluorescein angiography) results showed that F1 mice were able to reproduce the F0 phenotype.

    Figure 5. Fundus fluorescein angiography results of hVEGFA mice (F1).
     

    FFA (Fundus fluorescein angiography) results showed that F2 mice were able to reproduce the F0 and F1 phenotypes.

    Figure 6. Fundus fluorescein angiography results of hVEGFA mice (F2).
     

    Any anti-VEGF (human VEGF) AAVs and/or AAVs that can eventually carry therapeutic proteins can be tested well with the hVEGFA transgenic mice. The rod cells in the eyes of hVEGFA mice will specifically overexpress Humanized VEGFA protein and mice develop wAMD phenotype, which is stably inherited through F2 generation. For these reasons, hVEGFA mice are one of the best wAMD models to test for therapeutic antibodies and/or fusion proteins (e.g. small drugs, protein-based drugs, AAVs that can eventually carry therapeutic proteins). Cyagen's AI-AAV discovery platform can assist with your vector design and development needs.

    4. Other Established Eye Disease Models

    In addition to the hVEGFA mouse model mentioned above, Cyagen has also developed a series of gene-edited and humanized mouse models for diseases such as retinitis pigmentosa, congenital amaurosis, and achromatopsia. Cyagen also provides personalized custom services for researchers.

    Disease

       Target Gene

    Gene Targeting Type

    Macular degeneration

    hVEGFA

    KI、TG

    ABCA4(ABCR)

    KO、Humanization

    Pigmentary degeneration of retina

    RHO

    KO、CKO、Humanization、Humanization(Mu)

    Mertk

    KO、CKO

    Rpgr

    KO

    Crb1

    KO

    Rd1(Pde6b)

    KO、MU

    Rd10(Pde6b)

    MU

    RP2

    KO、CKO

    Retinal degeneration

    Tub

    KO

    Late-Onset Retinal Degeneration

    Rds(Prph2)

    KO

    Leber congenital amaurosis type 2

    Rpe65

    KO、MU

    Leber congenital amaurosis type 4

    Aipl1

    KO

    Leber congenital amaurosis type 10

    CEP290

    Humanization

    Leber congenital amaurosis type 13

    Rdh12

    KO

    Achromatopsia

    Cnga3

    CKO

    Fuchs endothelial dystrophy

    TCF4

    CKO、Humanization

    Congenital aniridia

    Pax6

    CKO

    Choroideremia 

    Chm

    CKO

    Usher Syndrome

    USH2A

    Humanization

    Myo7a

    CKO

    Vitelliform macular degeneration

    Best1

    KO

    X-linked retinoschisis

    Rs1

    KO、CKO

    Oculocutaneous albinism type 1

    Tyr

    CKO

    Oculocutaneous albinism type 3

    Tyrp1

    KO、CKO

    Wolfram Syndrome

    Wfs1

    KO、CKO

    Pseudoxanthoma elasticum

    Abcc6

    KO、CKO

    Original Article


 Products

  • Cyagen Knockout Catalog Models
    Over 16,000 Strains of KO and cKO Mouse Models | 100% Pure B6 Background | Delivered as Fast as 2 Weeks...

  • The Cyagen Knockout Catalog Models repository provides a searchable listing of over 16k mouse strains in more than 20 research fields, including oncology, cardiology, and neurology. You can quickly query the required genetically engineered global knockout (KO) mouse, conditional knockout (cKO/floxed) mouse and microRNA KO mouse strains by simply entering the gene name. The powerful database offers you a more convenient experience by streamlining the process of identifying KO mouse models and ordering them for research.

    Knockout Mice | Ready-to-Use KO Mice Model

    Knockout Models for Every Research Field

    Cyagen subdivides different mouse models into applied research fields and provides detailed information about the backgrounds and associated applications of the models to help simplify the model selection process.

    Oncology
    Neuroscience
    Immunology
    Cardiology
    Ophthalmology
    Metab
  • Custom Genetically Modified Mouse and Rat Models
    CRISPR, Transgenic, ES Cell-mediated gene editing for mouse and rat models. Our proprietary TurboKnockout® technology is free of patent disputes, providing FTO for drug development projects....

  • Our comprehensive services cover the entire process of model generation: from transgenic/gene targeting strategy design, through model development, breeding, cryopreservation, and phenotype analysis. 

    Transgenic Mice and Rat Models

    Cyagen provides comprehensive model generation services for all your transgenic mouse, mouse embryo, and rat model needs. 

    Cyagen’s Transgenic Rodent Model Generation Capabilities

    Regular Transgenic PiggyBac Transgenic ROSA26 Large-Fragment Knockin
    Integration Random, multicopy integration Random, single copy per integration site Single copy transgene targeted to ROSA26 safe harbor locus
    Vector construction Transgenic plasmid or BAC Transgenic plasmid or BAC Targeting vector + gRNAs
    Expression pattern Variable expression in founders More consistent expression in founders Most consistent expression
    Zygosity Hemizygous Hemizygous Options: Heterozygous and Homo
    Endogenous effects Can disrupt endogenous gene expression Less likely to disrupt endogenous gene expression Safe harbor site (SHS) does not disrupt endogenous gene expression
    Available Services
    Turnaround time 2-5 months 6-9 months
    Donor background Mouse strains: C57BL/6, FVB
    Rat strains: Sprague-Dawley (SD), Long Evans
    Please inquire for the availability of additional strains.

    >> Learn more about Transgenic Services

    Custom CRISPR Mouse and Rat Models

    Cyagen’s CRISPR-based gene targeting services can generate custom mice and rats – including conventional knockout, conditional knockout, large-fragment knockin (LFKI), and humanization models - in as fast as 3 months.

    What Are the Advantages of CRISPR/Cas9-based Technology?

    Compared with other gene editing technologies, the key advantages of CRISPR/Cas9 are its high efficiency, rapid turnaround, low cost, convenient process, and successful application to different species. CRISPR/Cas9 significantly reduces turnaround time compared with traditional embryonic stem (ES) cell-mediated gene targeting due to its direct application in embryo. Our AI-based bioinformatics tools, such as AlphaKnockout, rapidly identify the optimal sequences for guide RNAs (gRNAs) to minimize off-target effect and guarantee the desired genotype is successfully introduced. 

    Cyagen’s CRISPR/Cas9 Rodent Model Generation Capabilities

    Service Advantages Model Generation Capabilities
    CRISPR/Cas9-based Mouse and Rat Generation Service
    • Large genetic alterations: Up to 15 kb knockin and 400 kb knockout.
    • Precise: Targeted insertions express your target gene accurately.
    • Efficient: Our unique fertilization process improves homology-directed repair (HDR) efficiency.
    • Guarantee: 100% money-back guarantee.
    • Short timeline: F0 animals as fast as 3 months
    Donor Strains Mouse: C57BL/6, FVB
    Rat: SD, Wistar, Long Evans, F344
    Please inquire for the availability of additional strains.

    Proprietary TurboKnockout® Gene Targeting Mouse Models

    Compared with CRISPR/Cas9-based techniques, TurboKnockout® is free of patent disputes, provides precise mouse models on a comparable timeline, and is the technology of choice among our clients performing drug development projects.

    The TurboKnockout® gene targeting service brings together the advantages of each method to provide complex gene modeling in C57BL/6 or BALB/c mouse models - including large-fragment knockins (LFKIs) up to 300 kb - on an accelerated timeline.

    TurboKnockout® delivers research-ready conditional knockout, reporter knockin, and humanization mouse models in as fast as 6 months.

    >> Learn more about TurboKnockout

    Custom Rat Models

    Rats are physiologically, morphologically, and genetically closer to humans than mice, making them an ideal animal model for human disease research. The genomic congruence of rats and humans contributes to the greater physiological similarities seen between the species. Compared to mice, rats are more capable of learning tasks and more advanced in terms of cognition and memory, which make it a popular animal model for physiological and behavioral studies human diseases research.

    >> Learn more about Custom Rat services

  • CRO Services for Immune Cell Therapy
    Antibody Development, CAR Molecule Design and Lentivirus Preparation, Immune Cell Preparation, Immune Cell Phenotype Testing, In Vitro & In Vivo Efficacy Evaluations...

  • As a promising field in cancer treatment, immunotherapy is expected to be a potential breakthrough in "curing" cancers. A significant development in this field is the chimeric antigen receptor T (CAR-T) cell therapy, which has demonstrated remarkable results in treating blood cancers like leukemia and lymphoma. To broaden the application range for CAR-T cell therapies, researchers have generated allogeneic, or universally-applicable, CAR-T cells by removing TCR and CD52 in order to avoid graft versus host disease (GVDH).

    At the same time, many researchers have focused their attention on researching the potential applications of CAR on relatives of T cells’- our natural killer (NK) cells. Compared with T cells, NK cells have a unique mechanism which does not require pre-activation to stimulate its immune function, and the recognition of the target is not limited by the presence of major histocompatibility (MHC) molecules. Thus, CAR-NK cells are suitable for allogeneic cell therapy, or universal patient applications from a single set of standardized cells. In addition, CAR-NK cell therapy has weaker side effects and typically does not cause severe CRS or neurotoxic effects as seen with CAR-T cells. Given that CAR-NK cells offer unique advantages over CAR-T cells, CAR-NK cell therapies have become a rapidly growing area of research.

    Drawing on years of research experience in tumor immunology, Cyagen offers a full range of services to support research and development of CAR-T/-NK and other cell therapies, including antibody development, CAR molecular design, CAR lentivirus preparation, immune cell preparation and phenotype testing, cell and animal model construction, and in vitro/in vivo efficacy evaluation.

    Cyagen Custom Immune Cell Therapy Research Services

    Antibody Development
    • ● Animal immunization
    • ● Cell fusion and screening
    • ● Subclone screening and amplification
    • ● Hybridoma sequencing
    • ● Functional validation
    • >> Learn More
    CAR Molecule Design and Lentivirus Preparation
    • ● CAR molecule design and vector construction
    • ● CAR lentivirus preparation
    • ● Stable cell line construction for target antigens
    • >> Learn More
    Immune Cell Preparation
    • ● T and CAR-T cell
    • ● NK and CAR-NK cell
    • ● Universal CAR-T cell
    • ● Murine CAR-T cell
    • >> Learn More
    Immune Cell Phenotype Testing
    • ● T cell immune phenotype analysis: activation, exhaustion, and memory phenotypes, etc.
    • ● NK cell phenotype analysis
    • ● Myeloid cell phenotype analysis
    • ● Others
    • >> Learn More
    In Vitro Efficacy Evaluation
    • ● CAR-T/NK cell proliferation service
    • ● CAR-T/NK cell cytotoxicityservice
    • ● Antibody dependent cellular cytotoxicity service
    • ● Macrophage antibody-dependent cellular phagocytosis (ADCP) assay service
    • ● Cytokine detection service
    • >> Learn More
    In Vivo Efficacy Evaluation
    • ● CDX tumor model constructed based on C-NKG and other immune-deficient mice
    • ● Syngeneic tumor model in mice
    • ● Humanized mouse models of the immune system: PBMC and HSC humanization
    • ● Drug administration
    • ● Tumor growth monitoring
    • ● Biochemical analysis of tissues and biological samples
    • >> Learn More
  • Customized Cell Lines and iPSCs
    Custom Knockout, Knockin, Point Mutation, Overexpression Cell Lines & induced pluripotent stem cells (iPSCs)....

  • Cyagen is the world`s leading provider of custom genome editing services. Leverage our experts and optimized CRISPR/Cas9 cell line modeling service platform CRISPR-Pro for a hassle-free research. CRISPR-Pro enables large fragments excision or correct mutations in various cell lines.
    Knockout Cell Lines
    Knockout Cell Lines

    Cyagen’s Smart-CRISPR™ cell line modeling services enable large fragment excision or accurate mutation(s) – providing knockout cell lines with complete loss-of-function of the target gene.

    more ›
     
    Knockin Cell Lines
    Knockin Cell Lines

    Custom stable knockin cell line generation with low price, rapid turnaround, and stable expression. CRISPR-Pro technology enables large fragment knockin in variety of mammalian cell lines.

    more ›
     
    Point Mutation Cell Lines
    Point Mutation Cell Lines

    Custom stable point mutation cell line generation service. Precise point mutations and stable expression in variety of cell lines with low price and rapid turnaround.

    more ›
     
    Overexpression Cell Lines
    Overexpression Cell Lines

    Gene overexpression, inducible gene expression, gene knockout, gene knockdown all can be achieved by custom lentiviral-based stable cell line service. Low price with a comprehensive cell repository.

    more ›
     

    Lentivirus Packaging

    We use 3rd generation lentiviral systems for the highest biosafety standards. Several additional viral sequences must be acquired from the packaging plasmids via recombination.

    more ›

    iPSC Disease Models: CRISPR-Edited and Stable Transfected

    Our in vitro disease model research platform provides genetically edited iPSCs that retain pluripotency and can help facilitate the creation of isogenic cell line disease models.

    Induced pluripotent stem cells (iPSCs) provide an ideal in vitro platform for studying disease mechanisms and developing cell therapy approaches, as they can be derived from cells with a singular genetic background and tailored to replicate specific disease phenotypes.

    When combined with gene editing techniques, iPSCs can be used to explore the mechanisms of disease, and develop effective new drugs and cell therapies. Cyagen’s iPSC disease model research platform has mature gene editing technologies and stem cell culture systems; it has overcome many difficulties related to iPSC cultivation, genetic modification, and monoclonalization.

    Additionally, we provide one-stop preclinical CRO capabilities for developing new drugs and cell therapies, including phenotype analysis, construction and testing of in vitro models for various disease application scenarios, and even drug efficacy (pharmacokinetics/pharmacodynamic) evaluations. You are welcome to contact us at 800-921-8930 or email to animal-service@cyagen.com for free project consultations.

    more ›

  • Virus Services: AAV/LV Design, Packaging, & Evals
    Cyagen's high-throughput AAV vector discovery platform helps overcome the present limitations of gene therapy R&D by quickly identifying next-generation AAV capsids that have enhanced tissue targeting capability, tissue specificity, and productivity....

  • Adeno-associated virus (AAV) is a DNA virus that has a single-stranded DNA genome. In contrast, lentiviruses are RNA viruses. Both AAV and Lentivirus are efficient gene delivery systems. They effectively transfer genes into mammalian cells.

    Cyagen has many years of experience in virus packaging platforms and can provide AAV, LV, ADV, and other viruses that comply with different quality standards. Our virus packaging platform has been widely used in constructing various cell line models and in vivo studies of living animals. It has been cited and published by customers in many documents. Our experts will work with you to ensure that you receive AAV, lentivirus, and adenovirus packaging services that are customized to your research at every stage, tailored to your needs.

    Adeno-associated Virus Packaging

    Adeno-associated viruses (AAVs) are promising therapeutic viral vectors. Cyagen can provide adeno-associated virus vectors design and delivery services. For AAV virus packaging, we adopt a three-plasmid co-transfection method. The advanced purification process can provide customized AAV packaging services with high purity, high titer, and different serotypes. It is especially suitable for in vivo animal experiments and can meet the personalized choices of gene therapy researchers.

    >> Check out more details on Adeno-associated virus packaging

    Lentivirus Packaging

    Lentiviruses are a powerful gene delivery vector that ensures the long-term expression of your target transgene. For Lentivirus packaging, we use 3rd generation lentiviral systems for the highest biosafety standards. Based on our rich experience in virus packaging platforms, Cyagen provides lentivirus (LV) packaging services with different quality standards, which are widely used in the construction of various cell line models, especially for difficult-to-infect T cells used in CAR T-cell construction.

    >> Check out more details on Lentivirus packaging

    Adenovirus Packaging

    Adenovirus (AdV) is a non-enveloped virus with a diameter of about 90-100nm, which has a wide range of cell and tissue infection capabilities, and the capacity of adenovirus vectors to carry gene fragments can reach 7-8kb. The adenovirus packaging system includes one expression plasmid and one or more helper plasmids. The target gene is expressed independently from the host cell genome, which can achieve rapid and high-abundance expression of the target product while avoiding gene mutation caused by gene integration.

    >> Check out more details on Adenovirus packaging

    Comparison of Adeno-associated Virus (AAV), Adenovirus (AdV), and Lentivirus (LV) Vectors

    Project AAV ADV LV
    Particle diameter 20-30nm 90-100nm 80-100nm
    Genome 4.7kb single-stranded DNA or 2.4kb double-stranded DNA 36 kb double-stranded DNA 9.3 kb double-stranded RNA
    Capacity ≤4.5kb 8.3kb ≤6kb
    Expression Phased expression at medium to high level High-level transient expression Moderately stable expression
    Expression Duration Begin to express within 7-14 days, Begin to express in 1-2 days, Begin to express in 2-4 days,
    Generally 6 months to 24 months Lasts ≤ (2-4) weeks Lasts ≥6 months
    Diffusion capacity in vivo High High Ordinary
    Immunogenicity Very low High Low
    Integration method Small amount of targeted integration No integration High frequency random integration
    Advantages High yield, simple composition, good safety High yield and easy purification Low yield, stable expression
    Application Animal experiments Cell/animal larger gene overexpression Cell experiments

    Inquiries and Quote Requests

    Request a quote now. Alternatively, you can always email cell-service@cyagen.com to inquire about our services or obtain a quote for your project.

    Innovative "AI+CGT"service platform

    Combining wet-lab experiments, bioinformatics and AI, our team has collected a large amount of data and built many proprietary AI models for cell and gene (CGT) therapy research, providing a range of preclinical services including: prediction of human gene mutation pathogenicity, design of mouse disease models, and accelerate the discovery of novel CGT drugs, such as adeno-associated virus (AAV) vectors and CAR-T cell therapies.

    For example, utilizing AI and single-cell RNA-sequencing technologies, Cyagen's high-throughput AAV vector discovery platform helps overcome the present limitations of gene therapy R&D by quickly identifying next-generation AAV capsids that have enhanced tissue targeting capability, tissue specificity, and productivity. Cyagen has produced substantial experimental data for AI model training and developed proprietary machine learning algorithms to accelerate the AAV capsid identification and optimization processes compared to traditional directed evolution methods.

    At the same time, Cyagen also provides full support for cell therapy R&D. Cyagen’s fully-humanized antibody screening platform allows discoveries of novel antibody drugs and CAR-T cell therapy drugs. Combined with our virus packaging, mouse model construction and pharmacodynamic CRO capabilities, we provide one-stop solutions for all stages of preclinical cell therapy R&D.